Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) posted its quarterly earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.08, FiscalAI reports. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $10.49 million.

Voyager Therapeutics Price Performance

Shares of VYGR stock traded up $0.21 during trading hours on Monday, reaching $4.11. The stock had a trading volume of 486,511 shares, compared to its average volume of 591,388. The firm has a market capitalization of $228.52 million, a PE ratio of -1.90 and a beta of 1.32. The firm has a 50-day simple moving average of $3.85 and a 200-day simple moving average of $4.14. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $5.55.

Wall Street Analyst Weigh In

VYGR has been the topic of several research reports. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Finally, HC Wainwright lowered their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.75.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total value of $53,806.63. Following the completion of the transaction, the chief executive officer owned 484,060 shares in the company, valued at approximately $1,834,587.40. This represents a 2.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 49,783 shares of company stock worth $188,694. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in VYGR. Wexford Capital LP bought a new position in Voyager Therapeutics during the 3rd quarter valued at $42,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth $45,000. Coldstream Capital Management Inc. acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at $55,000. Virtu Financial LLC acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at $93,000. Finally, Occudo Quantitative Strategies LP bought a new position in Voyager Therapeutics during the second quarter valued at about $78,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.